Answers are grounded in this paper and cite their sources.
OBJECTIVES: While randomized controlled trials demonstrate omadacycline's efficacy and safety in community-acquired pneumonia (CAP), real-world evidence is sparse. This study evaluated clinical effectiveness, safety, and the factors influencing clinical success and 30-day mortality for CAP patients treated with omadacycline in real-world conditions. METHODS: We performed a study of CAP patients treated with omadacycline. The outcomes included clinical efficacy, 30-day mortality, microbial eradication, and adverse events. Multivariate logistic regression identified risk factors for clinical failure, with model performance assessed by Receiver Operating Characteristic (ROC) curves. Kaplan-Meier survival analysis and Cox proportional hazards regression were used to analyze prognostic factors. RESULTS: Among 150 patients, the clinical success rate was 86.0%. Multivariate analysis identified respiratory failure (OR 10.817, 95% CI 1.800-64.990) and higher Pneumonia Severity Index (PSI) score (OR 1.028, 95% CI 1.006-1.051) as independent risk factors for clinical failure. The ROC curve showed the area under the curve (AUC) value of the prediction model was 0.946 (95% CI: 0.904-0.989). The 30-day mortality rate was 6.7%. Kaplan-Meier analysis showed poorer survival for patients with Sequential Organ Failure Assessment (SOFA) score ≥2, PSI >130, age >80 years, ICU admission, or early clinical failure (P < 0.05). Cox regression confirmed early clinical failure (HR 0.031, 95% CI 0.001-0.710) and higher SOFA score (HR 1.500, 95% CI 1.076-2.091) independently predicted 30-day mortality. CONCLUSION: Omadacycline was effective and safe for CAP treatment in real-world practice, including elderly and comorbid patients.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: